Research Paper Volume 16, Issue 19 pp 12769—12780
Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling
Figure 2. Bezafibrate ameliorated release of the myocardial injury indicators in CME rats. (A) The CK-MB level; (B) The AST level; (C) The LDH level (n=12, **, p<0.01 vs. control group; #, ##, p<0.05, 0.01 vs. CME group).